Computer-aided detection developer iCAD and 3D software provider TeraRecon have signed a nonexclusive product licensing and distribution agreement.
Under the terms of the three-year deal, San Mateo, CA-based TeraRecon will develop a server-based product to include iCAD's lung cancer detection, analysis, and tracking software in various configurations. The server will be a standalone product designed to work in concert with existing PACS and DICOM review equipment and other products in TeraRecon's Aquarius product line, according to iCAD of Nashua, NH, and TeraRecon.
TeraRecon has licensed three CAD modules, including the firm's QuickCue package for automated detection of cancerous lung nodules, and QuickMatch software for automated location, comparison, and tracking of cancerous lung nodules in previous or subsequent patient studies. The third module, QuickChange, provides assistance in analyzing and evaluating lung cancers by providing quantitative descriptions of lesions based on contrast enhancement studies, according to the companies.
Worldwide distribution will take place through TeraRecon's direct sales force, independent resellers/distributors, and OEM partnerships. The server and associated advanced-review licenses will be offered to new TeraRecon customers, as well as the company's installed base. The companies anticipate product release in 2005.
By AuntMinnie.com staff writersJuly 12, 2004
Related Reading
iCAD, Siemens sign distribution deal, July 8, 2004
TeraRecon joins forces with Pentax, June 24, 2004
Fuji invests $5 million in TeraRecon, June 10, 2004
TeraRecon enters flat-panel area detector market, June 8, 2004
iCAD, Confirma form mammo/MR alliance, June 3, 2004
Copyright © 2004 AuntMinnie.com




















![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&fit=crop&h=112&q=70&w=112)